help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First Published Online May 7, 2009
The Oncologist, Vol. 14, No. 5, 497-510, May 2009; doi:10.1634/theoncologist.2008-0260
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2008-0260v1
14/5/497    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grossi, F.
Right arrow Articles by Pappagallo, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grossi, F.
Right arrow Articles by Pappagallo, G.

Lung Cancer

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Francesco Grossia, Marianna Aitab, Carlotta Defferraria, Francesco Rosettic, Annalisa Briantia, Gianpiero Fasolab, Orazio Vinantec, Paolo Pronzatoa, Giovanni Pappagalloc

aMedical Oncology A, Disease Management Team - Lung Cancer, National Institute for Cancer Research, Genova, Italy; bDepartment of Medical Oncology, University Hospital of Udine, Piazzale S. M. della Misericordia, Udine, Italy; cDepartment of Medical Oncology, Mirano Hospital, Via L. Mariutto, Mirano, VE, Italy

Key Words. Non-small-cell lung carcinoma • Meta-analysis • Gemcitabine • Docetaxel • Paclitaxel • Vinorelbine

Correspondence: Francesco Grossi, M.D., Medical Oncology A, Disease Management Team - Lung Cancer, National Institute for Cancer Research, Largo R. Benzi, 10, 16132 Genova, Italy. Telephone: 39-010-560-06-65 (office) or 39-335-525-54-84 (mobile); Fax: 39-010-560-08-50; e-mail: francesco.grossi{at}istge.it

Received December 1, 2008; accepted for publication March 24, 2009; first published online in THE ONCOLOGIST Express on May 7, 2009.

Disclosures: Francesco Grossi: Honoraria: Eli Lilly, Sanofi-Aventis, Roche; Marianna Aita: None; Carlotta Defferrari: None; Francesco Rosetti: None; Annalisa Brianti: None; Gianpiero Fasola: Honoraria: Roche, Eli Lilly, Sanofi-Aventis; Orazio Vinante: None; Paolo Pronzato: None; Giovanni Pappagallo: Honoraria: Eli Lilly, Sanofi-Aventis.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

Background. The therapeutic equivalence of different third-generation agents in the first-line treatment of advanced non-small cell lung cancer (NSCLC) has long been accepted, although recent studies seem to suggest some superiority of gemcitabine- or docetaxel-containing regimens over other third-generation doublets.

Objective. To assess the relative impact of different third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer by considering both response and progressive disease (PD) rates as outcome measures.

Methods. Published and unpublished data were collected from randomized trials comparing a gemcitabine-, docetaxel-, vinorelbine- or paclitaxel-containing regimen with one or more gemcitabine-, docetaxel-, vinorelbine- or paclitaxel-free combinations. For each study, 2 x 2 tables were constructed for both response and immediate progression. Pooled odds ratios were calculated using a general variance-based method.

Results Forty-five trials (11,867 patients) were eligible. The odds of obtaining an objective response to treatment were similar across different regimens. Gemcitabine-based chemotherapy was associated with a 14% lower risk for immediate progression, whereas patients receiving paclitaxel showed a 22% higher risk for having PD as the best response. Docetaxel treatment provided a nonsignificant 9% lower odds for progression.

Conclusions. These data demonstrate that different third-generation regimens have comparable activity in chemotherapy-naïve patients with advanced NSCLC. Gemcitabine-based chemotherapy provides better disease control, whereas the risk for immediate progression is significantly higher when paclitaxel-containing regimens are used.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.